Related Experiment Video
Updated: Jan 15, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.2K
Macrocyclic Compounds: Unveiling Their Distinctive Antiviral Advantages in Medicinal Research
Xiaopei Yang1,2,3,4, Zirui Jiao1,3, Chuangchuang Fan1,3
1Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China.
Journal of Medicinal Chemistry
|October 10, 2025
Summary
Macrocyclic compounds show promise as novel antiviral drugs, offering unique structural advantages to combat viral infections and drug resistance. These agents effectively target multiple viral life cycle stages, complementing vaccines.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- Viral infections pose increasing global health threats, necessitating innovative therapeutic strategies beyond vaccines.
- Macrocyclic compounds have demonstrated success against Hepatitis C Virus (HCV), highlighting their antiviral potential.
- Existing FDA-approved macrocyclic drugs are being investigated for broader antiviral applications.
Purpose of the Study:
- To review recent advancements in antiviral macrocyclic drugs developed over the last decade.
- To analyze the structural advantages and structure-activity relationships of these macrocyclic compounds.
- To elucidate their molecular mechanisms of action against viral infections from both viral and host perspectives.
Main Methods:
- Comprehensive literature review of antiviral macrocyclic drugs from the past 10 years.
- Analysis of structural features contributing to antiviral efficacy.
- Examination of structure-activity relationships (SAR) and mechanisms of action.
Main Results:
- Macrocyclic structures offer unique advantages for targeting multiple stages of the viral life cycle.
- These compounds exhibit enhanced druggability and potential as antiviral targets.
- Structural features enable effective counteraction of viral immune evasion and drug resistance.
Conclusions:
- Macrocyclic drugs represent a promising class of antiviral agents with significant potential for clinical application.
- Their distinct mechanisms and structural attributes are crucial for overcoming challenges like drug resistance and immune evasion.
- Continued research into macrocyclic compounds is vital for developing next-generation antiviral therapies.
Related Concept Videos
00:56Viral Structure
73.8K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
73.8K
01:10Retrovirus Life Cycles
49.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.3K
01:29Microorganisms in Medicine and Therapeutics
960
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
960
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
149
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
149
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.7K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.7K